SAB Biotherapeutics, Inc.SABSNASDAQ
Loading
EBITDA Margin Over TimeStrong
Percentile Rank83
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Latest
0.00%
↑ 100% vs avg
Percentile
P83
Within normal range
Streak
1 yr
Consecutive growthStrong
Average
-597.84%
Historical baseline
PeriodValueYoY Change
20250.00%+100.0%
2024-2192.54%-28.7%
2023-1703.13%-2592.2%
2022-63.26%-153.4%
2021-24.96%-165.2%
202038.26%+116.0%
2019-239.22%-